Massachusetts General Hospital
- Type
- Teaching hospital
- Where
- Boston, MA
- Medicare CCN
- 220071
- Received
- $91,550,024 in 2,926 records, 2024 ($40,023,757 general, $51,526,266 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: MASSACHUSETTS GENERAL HOSPITAL (THE) Fuzzy (name and state)
- Business registration: The Massachusetts General Hospital Fuzzy (name and state)
- Business registration: THE MASSACHUSETTS GENERAL HOSPITAL INC. Fuzzy (name and state)
- Business registration: THE MASSACHUSETTS GENERAL HOSPITAL INC. Fuzzy (name and state)
- Nonprofit contractor: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Federal award recipient: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Federal award recipient: MASSACHUSETTS GENERAL HOSPITAL, THE Fuzzy (name and state)
- Nonprofit: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Patent assignee: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Trademark owner: MASSACHUSETTS GENERAL HOSPITAL, THE Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 611 | $40,023,757 |
| 2024 | Research payment | 2,315 | $51,526,266 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,315 | $51,526,266 |
| Royalty or License | 110 | $35,857,905 |
| Grant | 36 | $1,794,471 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 22 | $1,505,216 |
| Consulting Fee | 25 | $323,938 |
| Space rental or facility fees (teaching hospital only) | 9 | $240,862 |
| Long term medical supply or device loan | 40 | $170,671 |
| Debt forgiveness | 361 | $95,468 |
| Education | 6 | $30,800 |
| Charitable Contribution | 2 | $4,423 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | OCCLUTECH US LLC | $78,726 | Grant (9 payments) | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $66,420 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2,3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 mRNA-4157 in com | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $50,960 | Research payment | In-kind items and services | Biograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Case Studies and Publications on Biograph Vision | 2024 |
| 2024-12-31 | Philips North America LLC | $20,000 | Royalty or License | Cash or cash equivalent | (1399) MRI Equip Undiv Device, Medical Device | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $18,800 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO | 2024 |
| 2024-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO | 2024 |
| 2024-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO | 2024 |
| 2024-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO | 2024 |
| 2024-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO | 2024 |
| 2024-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO | 2024 |
| 2024-12-31 | Cambridge Interventional LLC | $6,000 | Long term medical supply or device loan | In-kind items and services | CRF Device, RFA | 2024 | |
| 2024-12-31 | AngioDynamics, Inc. | $4,800 | Long term medical supply or device loan | In-kind items and services | VenaCure 1470 Pro Device, ET | 2024 | |
| 2024-12-31 | Stryker Corporation | $4,445 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Stryker Corporation | $4,445 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Stryker Corporation | $4,445 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $4,248 | Research payment | In-kind items and services | ACUSON Sequoia Diagnostic Ultrasound System Device, US - Ultrasound Systems | Noninvasive Biomarkers of Metabolic Liver Disease NIMBLE Study11 | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $2,500 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $1,865 | Research payment | Cash or cash equivalent | syngo Dynamics Device, SY - Image and Knowledge Management | 2024 | |
| 2024-12-31 | COLOPLAST CORP | $1,844 | Debt forgiveness | Cash or cash equivalent | Titan Device, Men's Health | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $1,563 | Research payment | In-kind items and services | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate | 2024 | |
| 2024-12-31 | Impulse Dynamics (USA) Inc. | $1,000 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-12-31 | Impulse Dynamics (USA) Inc. | $1,000 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-12-31 | ABBVIE INC. | $882 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | M14-658 UPA UC Ph3 Peds | 2024 |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Stryker Corporation | $745 | Long term medical supply or device loan | In-kind items and services | NA Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $577 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | ABBVIE INC. | $525 | Research payment | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | M16-194 Skyrizi Ph3 PIP CD | 2024 |
| 2024-12-31 | ABBVIE INC. | $300 | Research payment | In-kind items and services | M23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study | 2024 | |
| 2024-12-31 | Masimo Corporation | $291 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $285 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, Devices | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $203 | Research payment | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descrip | 2024 |
| 2024-12-31 | Fisher & Paykel Healthcare Inc | $122 | Long term medical supply or device loan | In-kind items and services | FISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier | 2024 | |
| 2024-12-31 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2024 | |
| 2024-12-30 | PFIZER INC. | $240,000 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | EVIDENCE GENERATION STUDY TREATMENT AND CLINICAL CHARACTERISTICS OF PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTA | 2024 |
| 2024-12-30 | QIAGEN, LLC | $4,660 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $1,385 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $874 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $619 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $599 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $384 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $383 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $351 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $346 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $317 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $313 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $313 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $300 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $299 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $296 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $285 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $279 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $274 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $274 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $251 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $241 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $235 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $222 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $222 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $213 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $202 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $194 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $168 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $156 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $151 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $93 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $71 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $71 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $29 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $24 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | QIAGEN, LLC | $5 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-28 | JAZZ PHARMACEUTICALS INC. | $85,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-27 | Janssen Research & Development, LLC | $40,192 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-27 | Intuitive Surgical, Inc. | $12,207 | Royalty or License | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-12-27 | Intuitive Surgical, Inc. | $8,342 | Royalty or License | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-12-26 | BeiGene, Ltd. | $347,760 | Research payment | In-kind items and services | BRUKINSA Drug, Oncology | A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell | 2024 |
| 2024-12-24 | Amgen Inc. | $395,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-24 | GlaxoSmithKline, LLC. | $87,968 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | 0000000000000000000000000000000000000000000000000000000000000000214438 | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $7,800 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $5,720 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | GlaxoSmithKline, LLC. | $1,133 | Research payment | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 0000000000000000000000000000000000000000000000000000000000000000214438 | 2024 |
| 2024-12-23 | E.R. Squibb & Sons, L.L.C. | $5,600 | Research payment | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients with an Elevated D-Dimer | 2024 |
| 2024-12-23 | Genentech, Inc. | $2,850 | Research payment | Cash or cash equivalent | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | 2024 | |
| 2024-12-23 | Edwards Lifesciences Corporation | $1,820 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2024 | |
| 2024-12-23 | Bausch Health US, LLC | $1,487 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | $245,100 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of A | 2024 | |
| 2024-12-20 | PTC Therapeutics, Inc. | $12,352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | PROGENICS PHARMACEUTICALS, INC. | $9,862 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | 2024 |
| 2024-12-20 | W. L. Gore & Associates, Inc. | $4,770 | Research payment | Cash or cash equivalent | GORE CARDIOFORM Septal Occluder Device, Devices | GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P | 2024 |
| 2024-12-20 | BIOTRONIK INC. | $1,500 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2024 |
| 2024-12-20 | Medtronic, Inc. | $1,500 | Grant | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | 2024 | |
| 2024-12-19 | BeiGene, Ltd. | $151,200 | Research payment | In-kind items and services | BRUKINSA Drug, Oncology | A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell | 2024 |
| 2024-12-19 | E.R. Squibb & Sons, L.L.C. | $129,631 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | CVID (Common Variable Immune Deficiency) USID Net Registry Extension Study | 2024 |
| 2024-12-19 | Chiesi USA, Inc. | $70,080 | Grant | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | 2024 | |
| 2024-12-19 | Janssen Research & Development, LLC | $68,542 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | PFIZER INC. | $33,750 | Research payment | Cash or cash equivalent | PFIZER TRANSLATIONAL NEUROSCIENCE PTN FELLOWSHIP PROGRAM | 2024 | |
| 2024-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $25,968 | Research payment | In-kind items and services | NINLARO Drug, ONCOLOGY | X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT | 2024 |
| 2024-12-19 | Janssen Research & Development, LLC | $20,258 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | Ardelyx, Inc. | $9,262 | Consulting Fee | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-12-19 | Bausch Health US, LLC | $3,178 | Research payment | Cash or cash equivalent | Cancer prevention with laser: a pilot study to determine if fractional nonablative laser can alter dermal IGF-1 expressi | 2024 | |
| 2024-12-19 | Janssen Research & Development, LLC | $1,605 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2024 | |
| 2024-12-18 | GE HEALTHCARE | $1,185,741 | Research payment | Cash or cash equivalent | DEFINE/DEVELOP LEARNING PLATFORM | 2024 | |
| 2024-12-18 | PFIZER INC. | $18,500 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | CONJUGATE VS CARBOHYDRATE VACCINE COMPARATIVE STUDYWI233503 | 2024 |
| 2024-12-18 | Bolton Medical Inc | $16,350 | Research payment | Cash or cash equivalent | RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | EXTEND | 2024 |
| 2024-12-18 | Tanabe Pharma America, Inc. | $3,191 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILIT | 2024 | |
| 2024-12-18 | Chiesi USA, Inc. | $1,628 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,616 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,217 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,122 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,001 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $503 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Cala Health, Inc. | $416 | Research payment | In-kind items and services | The wandering nerve; gateway to boost Alzheimer's disease related cognitive performance | 2024 | |
| 2024-12-18 | Cala Health, Inc. | $259 | Research payment | In-kind items and services | The wandering nerve; gateway to boost Alzheimer's disease related cognitive performance | 2024 | |
| 2024-12-18 | Cala Health, Inc. | $130 | Research payment | In-kind items and services | Brain Mechanisms of Vagus Nerve Stimulation and Stress Reduction Training for Migraine | 2024 | |
| 2024-12-18 | QIAGEN, LLC | $77 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | QIAGEN, LLC | $46 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | QIAGEN, LLC | $29 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | PTC Therapeutics, Inc. | $50,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | PTC Therapeutics, Inc. | $7,943 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Ultragenyx Pharmaceutical Inc. | $6,935 | Research payment | Cash or cash equivalent | UX701-CL301 | 2024 | |
| 2024-12-17 | Boston Scientific Corporation | $3,133 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | OCCLUDE | 2024 |
| 2024-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $600 | Research payment | Cash or cash equivalent | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2024 | |
| 2024-12-17 | PTC Therapeutics, Inc. | $452 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Medtronic, Inc. | $90 | Research payment | Cash or cash equivalent | ADAPT-PD Trial | 2024 | |
| 2024-12-16 | SANOFI US SERVICES INC. | $97,539 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-16 | TransMedics, Inc. | $70,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (12 payments) | Cash or cash equivalent | Organ Care System Device, Device | 2024 | |
| 2024-12-16 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2024 |
| 2024-12-16 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | $39,802 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2024 | |
| 2024-12-16 | Janssen Research & Development, LLC | $25,480 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2024 | |
| 2024-12-16 | SANOFI US SERVICES INC. | $24,640 | Research payment | Cash or cash equivalent | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient | 2024 | |
| 2024-12-16 | Insmed, Inc. | $2,335 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 | |
| 2024-12-16 | Biosense Webster, Inc. | $2,298 | Research payment | Cash or cash equivalent | Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Abla | 2024 | |
| 2024-12-16 | Insmed, Inc. | $2,141 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 | |
| 2024-12-16 | QIAGEN, LLC | $52 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $49,096 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $8,978 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Calyxo, Inc. | $8,019 | Royalty or License | Cash or cash equivalent | CVAC ASPIRATION SYSTEM Device, Urology | 2024 | |
| 2024-12-13 | Biosense Webster, Inc. | $5,788 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-12-13 | W. L. Gore & Associates, Inc. | $4,537 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter cl | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | W. L. Gore & Associates, Inc. | $898 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter cl | 2024 |
| 2024-12-13 | Merit Medical Systems Inc | $460 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-13 | Merit Medical Systems Inc | $405 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Sage Therapeutics, LLC | $99,042 | Research payment | Cash or cash equivalent | National Pregnancy Registry for Psychiatric Medications | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $26,236 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-12-12 | Roche Diagnostics Operations, Inc. | $26,110 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2024 |
| 2024-12-12 | Biogen, Inc. | $15,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Roche Diagnostics Operations, Inc. | $9,798 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2024 |
| 2024-12-12 | Genentech, Inc. | $5,891 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2024 |
| 2024-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200 | Research payment | Cash or cash equivalent | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2024 | |
| 2024-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | $600 | Research payment | Cash or cash equivalent | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2024 | |
| 2024-12-12 | Abbott Laboratories | $25 | Research payment | In-kind items and services | FLEXABILITY Device, ELECTROPHYSIOLOGY | VT PAS Study | 2024 |
| 2024-12-11 | JAZZ PHARMACEUTICALS INC. | $15,127 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solu | 2024 |
| 2024-12-11 | SANOFI US SERVICES INC. | $5,150 | Research payment | Cash or cash equivalent | FABRAZYME Biological, Genetic Disease | Fabry Disease Registry Protocol | 2024 |
| 2024-12-11 | Medtronic, Inc. | $2,068 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-11 | Bausch Health US, LLC | $419 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-12-11 | Medtronic, Inc. | $124 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-11 | Medtronic, Inc. | $124 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-10 | Servier BioInnovation | $79,766 | Research payment | In-kind items and services | Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | 2024 | |
| 2024-12-10 | Boston Scientific Corporation | $4,862 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-12-10 | Cook Research Incorporated | $4,000 | Research payment | Cash or cash equivalent | CMH-1707 | 2024 | |
| 2024-12-10 | United Therapeutics Corporation | $3,422 | Research payment | Cash or cash equivalent | TYVASO Drug, Progressive Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $2,300 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $983 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | HI-PEITHO | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-12-09 | BeiGene, Ltd. | $90,720 | Research payment | In-kind items and services | BRUKINSA Drug, Oncology | A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | Servier BioInnovation | $21,934 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-12-09 | SANOFI US SERVICES INC. | $17,195 | Research payment | Cash or cash equivalent | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient | 2024 | |
| 2024-12-09 | SANOFI US SERVICES INC. | $16,080 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-09 | Medtronic, Inc. | $2,955 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-12-09 | Medtronic, Inc. | $2,955 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-12-09 | Edwards Lifesciences Corporation | $1,040 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2024 | |
| 2024-12-06 | SANOFI US SERVICES INC. | $113,286 | Research payment | Cash or cash equivalent | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient | 2024 | |
| 2024-12-06 | Regeneron Pharmaceuticals, Inc. | $54,297 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA | 2024 |
| 2024-12-06 | RECORDATI_RARE_DISEASES_INC. | $1,000 | Research payment | Cash or cash equivalent | OSILODROSTAT Drug, ENDOCRINE AGENT | LCI699-RECAG-PASS-0572 | 2024 |
| 2024-12-05 | PFIZER INC. | $300,000 | Research payment | Cash or cash equivalent | PSYCHOMETRIC VALIDATION OF A NEW LONG COVID PATIENT REPORTED OUTCOMES PRO INSTRUMENT PROSPECTIVE OBSERVATIONAL STUDY FOR | 2024 | |
| 2024-12-05 | Zimmer Biomet Holdings, Inc. | $127,672 | Research payment | Cash or cash equivalent | Vanguard Complete Knee Solution Device, Knees | Study Management for E1 Tibial Bearing Study | 2024 |
| 2024-12-05 | Edwards Lifesciences Corporation | $23,007 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-12-05 | NIDEK CO., LTD. | $20,000 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | Cala Health, Inc. | $14,400 | Research payment | In-kind items and services | Evaluation of Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation on the Modulation of Disease Activity and Inf | 2024 | |
| 2024-12-05 | JAZZ PHARMACEUTICALS INC. | $8,500 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | Evaluation of Cannabidiol for Reduction of Brain Neuroinflammation | 2024 |
| 2024-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,832 | Research payment | Cash or cash equivalent | BI 1015550 - Ph3 Open Label Extension | 2024 | |
| 2024-12-05 | Roche Diagnostics Operations, Inc. | $3,747 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $298 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $298 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
The latest 200 records of 2,926.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments